Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Insight - Rare diseases and changes for the common good

This article was originally published in Scrip

Executive Summary

An orphan medicinal product is defined as a product to treat life-threatening or serious debilitating conditions for which no, or no satisfactory, alternative exists. The current EU definition of rare diseases is a prevalence of less than five cases per 10,000 persons. The European Union Orphan Medicinal Product (OMP) Regulation was introduced in 2000 with the remit of providing timely and equitable access to therapies for patients with rare diseases, and to balance risk by providing economic and other incentives to industry to develop such therapies.

You may also be interested in...



2011 Scrip Asia 100 - Abbott bullish about India but must work hard to retain crown

One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.

2011 Scrip Asia 100 - Asia life science-focused VC firms

Asia life science-focused VC firms*

2011 Scrip 100: Re-engineering Roche

Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel